AMD112 is a non-invasive HA-conjugated small molecule therapy designed for wet age-related macular degeneration (wAMD) and other neovascular retinal diseases. Under HylRetinX™ platform, AMD112 enables oral or topical (eyedrop) administration with targeted delivery to the retina through CD44-mediated translocation across the blood-retinal barrier (BRB).
Despite the success of anti-VEGF injections, unmet needs remain in wAMD treatment, including poor accessibility, injection-related adverse events, and limited options for combination therapy.
AMD112 offers a non-biologic, small-molecule alternative capable of reaching the retinal layer without injection, potentially transforming the standard of care.
• Efficacy: Demonstrated significant lesion size reduction in a laser-induced CNV model
• Next Steps: Optimization of oral formulation and MOA confirmation underway